DK0526488T3 - Benzylphosphonsyre-tyrosinkinaseinhibitorer - Google Patents

Benzylphosphonsyre-tyrosinkinaseinhibitorer

Info

Publication number
DK0526488T3
DK0526488T3 DK91907740.4T DK91907740T DK0526488T3 DK 0526488 T3 DK0526488 T3 DK 0526488T3 DK 91907740 T DK91907740 T DK 91907740T DK 0526488 T3 DK0526488 T3 DK 0526488T3
Authority
DK
Denmark
Prior art keywords
tyrosine kinase
pct
benzylphosphonsyre
kinase inhibitors
sec
Prior art date
Application number
DK91907740.4T
Other languages
English (en)
Inventor
Robert Lee Dow
Steven Wayne Goldstein
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0526488T3 publication Critical patent/DK0526488T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK91907740.4T 1990-04-02 1991-03-14 Benzylphosphonsyre-tyrosinkinaseinhibitorer DK0526488T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50318890A 1990-04-02 1990-04-02

Publications (1)

Publication Number Publication Date
DK0526488T3 true DK0526488T3 (da) 1995-04-24

Family

ID=24001079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91907740.4T DK0526488T3 (da) 1990-04-02 1991-03-14 Benzylphosphonsyre-tyrosinkinaseinhibitorer

Country Status (12)

Country Link
US (1) US5326905A (da)
EP (1) EP0526488B1 (da)
JP (1) JPH0662650B2 (da)
AT (1) ATE114661T1 (da)
CA (1) CA2078214C (da)
DE (1) DE69105495T2 (da)
DK (1) DK0526488T3 (da)
ES (1) ES2064101T3 (da)
FI (1) FI924427A (da)
IE (1) IE64067B1 (da)
PT (1) PT97214A (da)
WO (1) WO1991015495A1 (da)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
DE69618587T2 (de) * 1995-06-07 2002-08-29 Sugen Inc Chinazoline und pharmazeutische zusammensetzungen
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
AU6112896A (en) * 1995-06-07 1996-12-30 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
AU7392696A (en) * 1995-10-04 1997-04-28 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
AU6280196A (en) * 1996-06-18 1998-01-07 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US6682921B1 (en) 1996-08-21 2004-01-27 New York University Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
US6313158B1 (en) 1997-06-20 2001-11-06 Sugen, Inc. Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6114371A (en) * 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6353080B1 (en) 1997-06-26 2002-03-05 The Dow Chemical Company Flame retardant epoxy resin composition
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
HUP0004024A3 (en) * 1997-09-26 2001-10-29 Zentaris Gmbh Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
UA71555C2 (en) * 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
EP1049786A2 (en) 1998-01-21 2000-11-08 Sugen, Inc. Human orthologues of wart
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
WO1999043636A2 (en) 1998-02-27 1999-09-02 The United States Of America As Represented By Thesecretary Of The Department Of Health And Human Services Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
WO1999045920A2 (en) * 1998-03-13 1999-09-16 Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
JP2002522009A (ja) 1998-04-14 2002-07-23 スージェン・インコーポレーテッド Ｓｔｅ−２０関連蛋白質キナーゼ
CA2314156C (en) 1998-05-29 2010-05-25 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1117397A1 (en) 1998-08-31 2001-07-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
WO2000014105A1 (en) 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001027077A2 (en) * 1999-10-12 2001-04-19 Basf Aktiengesellschaft Hydroxysulfonylalkylene-, phosphonoalkylene- or difluoro(phosphononon)methyl- substituted benzene, or benzofuran derivatives as non-peptidic cdc25 inhibitors
EP1222273A2 (en) 1999-10-22 2002-07-17 PHARMACIA & UPJOHN COMPANY Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
WO2001042253A2 (en) 1999-12-13 2001-06-14 The Dow Chemical Company Phosphorus element-containing crosslinking agents and flame retardant phosphorus element-containing epoxy resin compositions prepared therewith
WO2001042359A1 (en) 1999-12-13 2001-06-14 Dow Global Technologies Inc. Flame retardant phosphorus element-containing epoxy resin compositions
US20020010203A1 (en) 1999-12-22 2002-01-24 Ken Lipson Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
SK12712002A3 (sk) 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
ATE297395T1 (de) 2000-02-28 2005-06-15 Sugen Inc 3-(pyrolyllacton)-2-indolinon verbindungen zur verwendung als kinase-hemmstoffe
EP1272200B1 (en) * 2000-03-31 2005-06-22 Angiogene Pharmaceuticals Ltd Divided dose therapies with vascular damaging activity
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DE60114229T2 (de) 2000-11-29 2006-07-06 Allergan, Inc., Irvine Verhinderung von transplantatabstossung im auge
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US20040191926A1 (en) * 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
US6765012B2 (en) 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US6559173B1 (en) 2001-09-27 2003-05-06 Allergan, Inc. 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
EP1446487A1 (en) * 2001-11-13 2004-08-18 Sugen, Inc. Mammalian protein phosphatases
US6541504B1 (en) 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
AU2003251397B2 (en) 2002-06-05 2009-10-01 Genentech, Inc. Compositions and methods for liver growth and liver protection
ATE375342T1 (de) 2002-08-02 2007-10-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US6747025B1 (en) 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
US6699863B1 (en) 2002-11-27 2004-03-02 Allergan, Inc. Kinase inhibitors for the treatment of disease
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
CN103265477B (zh) 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
JP2007501229A (ja) 2003-08-06 2007-01-25 スゲン，インコーポレイティド 強力なプロテインキナーゼ阻害剤としての幾何学的に束縛された３−シクロペンチリデン−１，３−ジヒドロインドール−２−オン類
PL1684750T3 (pl) 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2005114197A2 (en) * 2004-04-15 2005-12-01 Albert Einstein College Of Medicine Of Yeshiva University Activity-based probes for protein tyrosine phosphatases
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
EP1753772B1 (en) 2004-05-28 2016-12-28 Blue Cube IP LLC Phosphorus-containing compounds useful for making halogen-free, ignition-resistant polymers
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
CN1302001C (zh) * 2005-01-20 2007-02-28 申厚宝 邻氯苄基膦酸二甲酯生产工艺
CA2603826C (en) 2005-04-04 2013-03-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8338415B2 (en) 2006-01-24 2012-12-25 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
CA2669704A1 (en) 2006-11-16 2008-05-22 Allergan, Inc. Sulfoximines as kinase inhibitors
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
JP2010523652A (ja) 2007-04-13 2010-07-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍発生を制御する方法および腫瘍発生のリスクを診断する方法
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
JP2011504462A (ja) 2007-11-02 2011-02-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍の予防および治療のための方法および化合物
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
CN102197041A (zh) 2008-08-28 2011-09-21 陶氏环球技术有限责任公司 含磷化合物和包含其的聚合物组合物
MX2011011025A (es) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
IN2012DN02493A (da) 2009-09-03 2015-08-28 Allergan Inc
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
EP2890706A1 (en) 2012-08-31 2015-07-08 Westfälische Wilhelms-Universität Münster Methods and peptides for preventing and treating a bcr-abl and a c-abl associated disease
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
CA3099440A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
US20220127286A1 (en) * 2019-03-04 2022-04-28 Merck Patent Gmbh Ligands for nano-sized materials

Also Published As

Publication number Publication date
EP0526488A1 (en) 1993-02-10
ATE114661T1 (de) 1994-12-15
CA2078214C (en) 1995-03-28
DE69105495D1 (en) 1995-01-12
PT97214A (pt) 1992-01-31
IE911035A1 (en) 1991-10-09
WO1991015495A1 (en) 1991-10-17
JPH05502452A (ja) 1993-04-28
FI924427A0 (fi) 1992-10-01
JPH0662650B2 (ja) 1994-08-17
EP0526488B1 (en) 1994-11-30
DE69105495T2 (de) 1995-04-06
US5326905A (en) 1994-07-05
FI924427A (fi) 1992-10-01
ES2064101T3 (es) 1995-01-16
IE64067B1 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
ATE114661T1 (de) Benzylphosphonsäure-tyrosinkinaseinhibitoren.
DE69115280T2 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
ID21927A (id) Asam aminoalkanafosfonat tersubstitusi
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
NO992282D0 (no) Benzonaftyridiner som bronkialterapentika
NO971766D0 (no) Anvendelsen av dioksomorfoliner for bekjempning av endoparasitter, nye dioksomorfoliner samt deres fremstilling
FI931503A (fi) Indolderivat som antiallergiska och antiinflammatoriska aemnen
DK0471756T3 (da) Saccharinderivater, der er egnede som proteolytiske enzyminhibitorer, og fremstilling deraf
PT97680A (pt) Processo para preparacao de novos compostos sulfonilo e de composicoes farmaceuticas que os contem
DK0941221T3 (da) Substituerede dihydrobenzofuraner som PDE-inhibitorer
IL116231A (en) Dipeptide p-amidinobenzylamides with n-terminal sulfonyl or aminosulfonyl radicals as thrombin inhibitors
TR200100133T2 (tr) FKBP İnhibitörleri
FI860426A0 (fi) Primycinkomponenter samt foerfarande foer avskiljning av antibiotkomplex.
IT1284973B1 (it) Uso del sodio 2-mercaptoetansolfonato (mesna) in chirurgia
ES2098119T3 (es) Nuevas triazoloquinazolinas, su obtencion y empleo.
DE59905355D1 (de) Verwendung von katecholderivaten als proteinaseinhibitoren
AR005835A1 (es) Derivados aromaticos sustituidos del acido fosfonico.
DE68903268T2 (de) Verwendung von folinsaeurederivaten als plaettchenaggregationshemmstoffe.